Health

Key Senate panel weighs small biotech carveout in drug pricing reforms

WASHINGTON — A key Senate panel is seriously considering a new policy that would soften the blow of drug pricing reform for small biotech companies, according to two sources familiar with the talks. But the concession isn’t likely to win over the biotech industry.

The change would be part of a package of broader drug pricing reforms from Senate Finance Committee Chairman Ron Wyden (D-Ore.), who promised, vaguely, to protect the smaller companies earlier this year. But the specifics of his policy have been unclear until now, as Democrats in both chambers of Congress look to include some kind of drug pricing reform in the massive government spending bill they’re debating in earnest.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED



Most Related Links :
newsbinding Governmental News Finance News

Source link

Back to top button